Latest studies
- Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
This study is gathering important information about a rare kidney disease called atypical Hemolytic-Uremic Syndrome (aHUS). It looks at how the disease progresses and how safe new treatments like eculizumab and ravulizumab are for patients of all ages.
Atypical Hemolytic-Uremic SyndromePoland - AuthorisedPhase II and Phase III (Integrated)
An Operationally Seamless Phase 2/3, Randomized, Active -Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1
This study is testing a new weekly pill for HIV to see if it's as good as a daily pill people already take. It's for adults whose HIV is already under control. We want to check how safe and effective the new weekly treatment is.
HIV-1 InfectionPoland - Active not recruitingPHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.
Gastric NeoplasmsGastroesophageal AdenocarcinomaEsophageal AdenocarcinomaPoland - RecruitingPHASE3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This study looks at a new medicine, Maridebart cafraglutide, for people with heart failure and obesity. It aims to see if the medicine can reduce heart-related problems like hospital stays, improve symptoms, and help people live longer, alongside their usual heart failure care.
Heart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection FractionObesityPoland - Active not recruitingPHASE4
OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness
This study looks at a medicine called OM-85 to see if it can help young children, aged 6 months to 5 years, who get lots of chest infections and wheezing. We want to know if it's safe and effective at reducing how often they get ill.
Respiratory Tract InfectionsWheezing Lower Respiratory IllnessPoland - RecruitingPHASE3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
This study looks at a new medicine, abelacimab, for people with an irregular heartbeat (atrial fibrillation) who can't take usual blood thinners. It compares abelacimab to a dummy medicine to see if it can prevent strokes.
Atrial Fibrillation (AF)Poland - RecruitingPHASE2
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
This study is testing a new medicine, GSK4532990, for people aged 18-70 with liver damage caused by alcohol. We want to see if it's safe and if it helps the liver. Some people will get the medicine, others a dummy pill.
Liver Diseases, AlcoholicPoland - AuthorisedPhase II and Phase III (Integrated)
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma
This study looks at new ways to treat a type of skin cancer in the eye that has spread (metastatic uveal melanoma). It compares two drug combinations, RP2 with Nivolumab, against Ipilimumab with Nivolumab, to see which is safer and more effective.
metastatic uveal melanomaPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-2)
This study is testing a new medicine, dexpramipexole, for adults with severe asthma that affects their eosinophils (a type of white blood cell). We want to see if it reduces severe asthma attacks and improves breathing and quality of life over 52 weeks.
Severe Eosinophilic asthmaPoland - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaPoland - RecruitingPHASE3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
This study is testing a new medicine, volrustomig, for people with a type of head and neck cancer that hasn't spread and wasn't removed by surgery. It aims to see if volrustomig helps prevent the cancer from coming back after standard treatment like chemotherapy and radiotherapy.
Locally Advanced Head and Neck Squamous Cell CarcinomaPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
This study is looking at a new medicine called Vyvgart for people with Thyroid Eye Disease. It aims to see if the medicine can help reduce bulging eyes and improve eye health, compared to a dummy medicine, over 24 weeks.
Thyroid Eye Disease (TED)Poland - AuthorisedHuman Pharmacology (Phase I)- Bioequivalence Study
A Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamics of QL0911
This study is looking at a new medicine, QL0911, for two conditions: Immune Thrombocytopenia (low platelets) and Acute Radiation Syndrome (a serious illness from radiation exposure). It's an early-stage study to understand how the medicine works in the body.
Immune Thrombocytopenia, Hematopoietic Syndrome of Acute Radiation SyndromePoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
PHASE 2a OPEN-LABEL BASKET STUDY TO EVALUATE SAFETY AND PHARMACOKINETICS OF INF904, AN ORAL C5aR1 INHIBITOR, IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC SPONTANEOUS URTICARIA OR HIDRADENITIS SUPPURATIVA
This study is testing a new medicine called INF904 for people with chronic hives or hidradenitis suppurativa. Researchers want to see if it's safe, how much stays in the body, and if it causes any side effects. It's an early-stage study to learn more about this new treatment.
Moderate to Severe Chronic Spontaneous Urticaria (CSU) or Moderate to Severe Hidradenitis Suppurativa (HS)Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003, with Open Label Extension, in Patients with Treatment Resistant Depression
This study is testing a new nasal spray, BPL-003, for people with depression that hasn't responded to other treatments. Researchers are looking at different doses to see how well it works and if it's safe.
Treatment-Resistant Depression (TRD)Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PRESent-2)
This study is looking into a new medicine called SerpinPC for severe haemophilia A or B. It wants to see if SerpinPC can reduce bleeding in adults with these conditions, especially those who currently treat bleeds as they happen. Researchers will also check how safe the new medicine is.
Severe Hemophilia A or Moderately Severe to Severe Hemophilia BPoland - RecruitingPHASE2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, Imeroprubart, for adults with a nerve condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Researchers want to see if it's safe and helps improve symptoms compared to a dummy treatment.
Chronic Inflammatory Demyelinating PolyneuropathyPoland - Active not recruitingPHASE2
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
This study looks at a new drug, tulisokibart, for people with a lung condition called interstitial lung disease (ILD) linked to scleroderma. We want to see if it's safe and helps improve the condition.
Diffuse Cutaneous Systemic SclerosisInterstitial Lung DiseasePoland - RecruitingPHASE2
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
This study looks at new treatments for stomach or food pipe cancer that can be removed by surgery. It aims to see how safe and effective these new drugs or drug combinations are before and after the operation.
Gastroesophageal AdenocarcinomaPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A single arm, open-label study to evaluate the efficacy and safety of ABBV-668 in subjects with moderate to severe ulcerative colitis.
This study is testing a new medicine called ABBV-668 for people with moderate to severe ulcerative colitis. Doctors want to see if it helps improve the lining of the bowel after 8 weeks and if it's safe to use. It's a key step in understanding if this medicine could help patients.
Ulcerative ColitisPoland - Active not recruitingPHASE3
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
This study is testing a new medicine, selumetinib, for adults with a condition called Neurofibromatosis Type 1 (NF1). It focuses on people who have painful, non-removable growths called plexiform neurofibromas. We want to see if this medicine can help reduce symptoms and safely shrink these growths.
Neurofibromatosis 1Plexiform Neurofibroma (PN)Poland - Active not recruitingPHASE3
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
This study looks at a medicine called atezolizumab for people with a type of bladder cancer that has spread into the muscle. It checks if this medicine, given after surgery, can stop the cancer from coming back in those who show signs of tiny cancer cells in their blood.
Muscle-invasive Bladder CancerPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)
This study looks at a new medicine called BH-200 for adults with severe depression. It compares BH-200 to a dummy pill to see if it helps improve mood and daily life better, and if it's safe.
Major Depressive DisorderPoland - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory BCell Non Hodgkin Lymphoma (ZUMA-4)
This study is testing a new treatment called Tecartus for children and teenagers with certain types of blood cancer (leukaemia and lymphoma) that have come back after treatment. We want to see how safe it is and how well it works to help patients get better.
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Relapsed/Refractory B-cell non-Hodgkin lymphoma (r/r NHL)Poland - Active not recruitingPHASE3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
This study is looking at a new medicine called baricitinib for children aged 1 to 17 with a type of arthritis called systemic juvenile idiopathic arthritis (sJIA). It aims to see if baricitinib is safe and helps to reduce their symptoms.
Systemic Juvenile Idiopathic ArthritisPoland - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
This study is looking at a new medicine called JNJ-64264681 for people with non-Hodgkin lymphoma and chronic lymphocytic leukaemia. It's a very early-stage study to check if the medicine is safe, how it moves through the body, and what it does in the body.
non-Hodgkin lymphoma and chronic lymphocytic leukemiaPoland - Active not recruitingPHASE3
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
This study looks at a new drug, Luspatercept, for people with myelofibrosis and anaemia who need regular blood transfusions and are already taking a JAK2 inhibitor. We want to see if it helps reduce the need for transfusions.
Myeloproliferative DisordersMyelofibrosisPrimary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)
This study is testing a new combination medicine (MK-4280A) against standard chemotherapy for people with Hodgkin Lymphoma that has come back or not responded to previous treatments. We want to see if the new medicine can stop the cancer from growing for longer.
Relapsed or Refractory Classical Hodgkin LymphomaPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
J3P-MC-FTAF: An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis
This study is testing a new medicine, LY3871801, for adults with rheumatoid arthritis. It's a research study to see how well the medicine works and if it's safe compared to a dummy pill. We hope to find new ways to help people with this condition.
Rheumatoid ArthritisPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)
This study is looking at a new combination of two medicines, Lenvatinib and KEYTRUDA, for adults with a type of kidney cancer called non-clear cell renal cell carcinoma (nccRCC). It’s in an early stage of testing to see how well patients respond to the treatment.
Non-clear Cell Renal Cell CarcinomaPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
This study is testing a new combination of medicines for people with a type of breast cancer called triple-negative breast cancer that has spread or can't be removed with surgery. It aims to see if the new combination can help people live longer without their cancer getting worse.
Triple-Negative Breast Cancer (TNBC)Poland - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)
This study is looking for the best dose of a new medicine called BI 907828 (brigimadlin) for people with advanced cancers that have grown or spread. It's an early-stage study to understand how the medicine works in the body.
Advanced or metastatic solid tumorsPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
INCB 18424-319: A phase 3, double-blind, randomised, vehicle-controlled, efficacy and safety study of ruxolitinib cream in participants with Purigo Nodularis. Topical ruxolitinib evaluation in Prurigo Nodularis (TRuE-PN1)
This study is testing a new cream for Prurigo Nodularis, a skin condition causing very itchy bumps. It compares a cream with the active medicine to a plain cream, to see if the new medicine can help reduce itchiness and improve the skin condition over 12 weeks.
Prurigo NodularisPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome
This study is looking into a new medication called ARO-APOC3 for adults with a rare genetic condition called Familial Chylomicronemia Syndrome (FCS). Researchers want to see if this new medicine can help lower high levels of fats in the blood and if it's safe to use.
Familial Chylomicronemia Syndrome (FCS)Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
J4E-MC-IMMB: A Master Protocol for Randomized, Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis; J4E-MC-FR01: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis
This study is looking into new ways to treat adults with moderate to severe eczema (atopic dermatitis). Researchers want to see how well a new medicine, LY3454738, works and if it's safe. They will compare it to a dummy treatment over 52 weeks.
Atopic dermatitisPoland - RecruitingPHASE2
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
This study is looking for a new way to treat a type of arthritis called radiographic axial spondyloarthritis (r-axSpA). Researchers want to see if an experimental medicine, tulisokibart, can help reduce pain, stiffness, and swelling in the spine and hips for people with this condition.
Radiographic Axial SpondyloarthritisPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
C5541010 - A PHASE 2A, RANDOMIZED, DOUBLE BLIND, SPONSOR OPEN, PLACEBO CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY OF PF 07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY
This study is testing a new medicine, PF-07976016, to see if it helps adults with obesity lose weight safely. Participants will receive either the new medicine, a proven weight-loss drug called Saxenda, or a dummy medicine, to compare the effects.
Obesity, OverweightPoland - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination with Anti-cancer Agents in Participants with Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01)
This study looks at a new drug, AZD0022, for people with certain types of lung, bowel, and pancreatic cancer. Doctors want to see if it's safe, how the body handles it, and if it can help shrink tumours, both on its own and with other cancer drugs.
Non Small Cell Lung CancerColorectal CancerPancreatic Ductal AdenocarcinomaPoland - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
This study is testing a new medicine, GEN3014, for people with multiple myeloma or other blood cancers that have come back or not responded to previous treatments. It aims to see if the medicine is safe and how well it works.
Relapsed or Refractory Multiple Myeloma (RRMM)Diffuse Large B Cell Lymphoma (DLBCL)Acute Myeloid Leukemia (AML)Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
This study is looking at a new medicine called Fipaxalparant for people with a serious skin condition called diffuse cutaneous systemic sclerosis. It's a second-stage trial to see how well it works and if it's safe over about a year.
Diffuse Cutaneous Systemic SclerosisPoland - RecruitingPHASE3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
This study is looking into a new medication called AZD0780. It aims to see if this medicine can lower the risk of serious heart problems like heart attacks or strokes in people who have already had them, or in those at high risk of having one for the first time.
Cardiovascular DiseasePoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome
This study is looking at a new tablet, Paltusotine, for people with Carcinoid Syndrome. Researchers want to see if it's safe, how it works in the body, and if different doses have different effects. They will compare it to an existing treatment, Octreotide.
Carcinoid SyndromePoland - RecruitingPHASE3
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
This study is looking at a new medicine called Etelcalcetide for children aged 2-17 with kidney disease who are on dialysis. It aims to see if the medicine works well and is safe for a condition called secondary hyperparathyroidism.
Secondary HyperparathyroidismPoland - RecruitingPHASE2
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
This study is looking into a new medicine, calderasib, to treat certain advanced cancers. Researchers want to see if it can shrink these cancers, either alone or with another medicine called cetuximab, in people whose cancers have a specific genetic change (KRAS G12C mutation).
Neoplasm MalignantPoland - RecruitingPHASE2
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
This study tests a new medicine, BI 1815368, for people with diabetic macular edema (DME), an eye condition linked to diabetes. It aims to see if the medicine improves sight and to find the best dose. Participants take tablets for about 11 months.
Macular EdemaPoland - RecruitingNA
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
This study looks at whether regular brain scans alone are as good as scans plus radiation therapy for people with small cell lung cancer. It aims to see if avoiding radiation therapy can improve quality of life and brain health without making outcomes worse.
Limited Stage Small Cell Lung CancerExtensive-stage Small-cell Lung CancerPoland - Active not recruitingPHASE2
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
This study is testing a new medicine, BI 764524, for people with an eye condition called diabetic retinopathy. It aims to see if it improves their vision and how often it should be given.
Diabetic RetinopathyPoland - RecruitingPHASE3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
This study looks at a new treatment called Pumitamig for advanced non-small cell lung cancer that hasn't been treated before. It compares Pumitamig to an existing treatment, Pembrolizumab, in people whose cancer cells have a high level of a specific marker called PD-L1.
Non-Small Cell Lung Cancer (NSCLC)Poland - RecruitingPHASE3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
This study is looking into a new medication called efruxifermin for people with a kind of liver disease called NASH/MASH and scarring (fibrosis). It's a large study where some people get the medication, and others get a dummy treatment, to see if it's safe and helps improve the liver condition.
NASH With FibrosisMASH With FibrosisPoland - RecruitingPHASE2, PHASE3
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
This study is testing a new medicine, elenestinib, for a rare blood condition called indolent systemic mastocytosis. It compares the new medicine to a dummy pill (placebo) to see if it helps reduce symptoms that current treatments aren't fully controlling.
Indolent Systemic MastocytosisSmoldering Systemic MastocytosisPoland